As of 2025-12-20, the Relative Valuation of BioMark Diagnostics Inc (BUX.CN) is (0.02) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.44 CAD, the upside of BioMark Diagnostics Inc based on Relative Valuation is -103.5%.
The range of the Relative Valuation is (0.01) - (0.11) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.8x - 6.9x | 1.0x |
| Forward P/E multiples | 0.7x - 6.5x | 0.9x |
| Fair Price | (0.01) - (0.11) | (0.02) |
| Upside | -103.0% - -124.1% | -103.5% |
| Date | P/E |
| 2025-12-16 | -29.94 |
| 2025-12-15 | -29.94 |
| 2025-12-12 | -29.94 |
| 2025-12-11 | -30.55 |
| 2025-12-10 | -30.55 |
| 2025-12-09 | -30.24 |
| 2025-12-08 | -30.55 |
| 2025-12-05 | -29.02 |
| 2025-12-04 | -29.33 |
| 2025-12-03 | -29.33 |
| 2025-12-02 | -28.72 |
| 2025-12-01 | -28.72 |
| 2025-11-28 | -24.44 |
| 2025-11-25 | -22.00 |
| 2025-11-24 | -21.38 |
| 2025-11-20 | -21.69 |
| 2025-11-19 | -22.00 |
| 2025-11-18 | -21.38 |
| 2025-11-17 | -21.38 |
| 2025-11-14 | -20.77 |
| 2025-11-13 | -20.47 |
| 2025-11-12 | -19.55 |
| 2025-11-10 | -21.08 |
| 2025-11-07 | -21.08 |
| 2025-11-06 | -21.38 |
| 2025-11-05 | -21.08 |
| 2025-11-04 | -21.08 |
| 2025-11-03 | -20.77 |
| 2025-10-31 | -20.77 |
| 2025-10-30 | -20.77 |
| 2025-10-29 | -20.47 |
| 2025-10-27 | -20.77 |
| 2025-10-23 | -20.47 |
| 2025-10-22 | -20.77 |
| 2025-10-17 | -21.69 |
| 2025-10-16 | -20.16 |
| 2025-10-15 | -20.16 |
| 2025-10-14 | -19.55 |
| 2025-10-10 | -20.16 |
| 2025-10-09 | -20.77 |
| 2025-10-08 | -21.38 |
| 2025-10-07 | -22.00 |
| 2025-10-06 | -20.77 |
| 2025-10-03 | -19.55 |
| 2025-10-02 | -20.16 |
| 2025-10-01 | -19.55 |
| 2025-09-30 | -20.47 |
| 2025-09-29 | -20.16 |
| 2025-09-26 | -19.55 |
| 2025-09-24 | -19.55 |